RxDoctor Payments Data

Antwan Ahad, MD

Neurology · Secaucus, NJNPI 1083729917

Payments from drug & device makers

$44,073in general payments, 2019–2025

Across 1,892 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • EMD Serono, Inc.$4K
  • Biogen$3K
  • Lundbeck LLC$2K
  • SK Life Science, Inc.$2K
  • Lilly USA, LLC$2K
  • plus $26K from 54 others

What the payments were for

  • Speaking & faculty fees$1360%
  • Food & beverage$43,65799%
  • Education$2811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)270$5,093
EMD Serono, Inc.79$4,156
Biogen86$3,307
Lundbeck LLC67$2,083
SK Life Science, Inc.87$1,635
Lilly USA, LLC73$1,562
AstraZeneca(2 entities)46$1,548
Amneal Pharmaceuticals LLC70$1,541
Novartis99$1,497
Pfizer87$1,175
Bristol Myers Squibb51$1,100
Sunovion Pharmaceuticals Inc.50$968
Neurocrine Biosciences, Inc.46$920
Eisai Inc.34$916
Teva Pharmaceuticals USA, Inc.47$888
UCB, Inc.49$878
Axsome Therapeutics, Inc.11$819
Sumitomo Pharma America, Inc.44$661
Neurelis, Inc.29$624
Amgen(2 entities)29$617
E.r. Squibb & Sons, L.L.C.12$610
Genentech USA, Inc.26$608
Argenx US, Inc.19$563
Scilex Pharmaceuticals Inc.33$545
Medtronic(2 entities)5$489
Otsuka America Pharmaceutical, Inc.13$432
Sanofi14$419
MDD US Operations, LLC34$412
Supernus Pharmaceuticals, Inc.28$406
TG Therapeutics, Inc.3$400
Acadia Pharmaceuticals Inc20$396
Johnson & Johnson16$389
CSL Behring19$378
Avadel CNS Pharmaceuticals, LLC3$375
Kyowa Kirin, Inc.18$372
Monteris Medical Corporation4$364
Biohaven Pharmaceutical Holding Company Ltd.22$358
Novocure Inc.2$318
Impel Pharmaceuticals Inc.14$317
Acorda Therapeutics, Inc12$273
ANI Pharmaceuticals, Inc.8$236
Almatica Pharma LLC44$227
Grifols USA, LLC12$221
Azurity Pharmaceuticals, Inc.16$212
Jazz Pharmaceuticals Inc.7$203
Currax Pharmaceuticals LLC15$195
Abbott3$187
Biohaven Pharmaceuticals, Inc.16$184
GE HealthCare13$179
Avanir Pharmaceuticals, Inc.11$149
Catalyst Pharmaceuticals, Inc.2$140
Vanda Pharmaceuticals Inc.2$138
Imperative Care, Inc1$134
Noctrix Health, Inc.1$125
Philips North America LLC1$120
Octapharma USA, Inc.7$107
Upsher-smith Laboratories LLC6$87
Banner Life Sciences, LLC6$87
Arbor Pharmaceuticals, Inc.6$81
Adamas Pharmaceuticals, Inc.6$75

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,073 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$245,900
Medicare patients
364
Services billed
1,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5048$974,905
Gamunex-CImmune Globul G/Gly/Iga Avg 4631$247,323
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$203,168
RebifInterferon Beta-1a/Albumin13$134,518
BriviactBrivaracetam77$114,604
PlegridyPeginterferon Beta-1a13$103,505
IngrezzaValbenazine Tosylate12$102,545
Nurtec OdtRimegepant Sulfate56$93,357
AptiomEslicarbazepine Acetate51$81,037
UbrelvyUbrogepant41$65,008
BotoxOnabotulinumtoxina42$52,505
XcopriCenobamate42$49,133
RytaryCarbidopa/Levodopa68$46,612
XadagoSafinamide Mesylate21$45,687
HorizantGabapentin Enacarbil43$44,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$1,175$1,071,435116 claims
Grifols USA, LLCGamunex-C$221$247,32331 claims
CSL BehringPrivigen$378$203,16815 claims
AbbVieUbrelvy, Botox, Qulipta, Namzaric, Linzess$5,093$187,513158 claims
UCB, Inc.Briviact, Neupro, Vimpat$878$164,370128 claims
EMD Serono, Inc.Rebif$4,156$134,51813 claims
BiogenPlegridy$3,307$103,50513 claims
Neurocrine Biosciences, Inc.Ingrezza$920$102,54512 claims
Sunovion Pharmaceuticals Inc.Aptiom$968$81,03751 claims
SK Life Science, Inc.Xcopri$1,635$49,13342 claims
Amneal Pharmaceuticals LLCRytary$1,541$46,61268 claims
Arbor Pharmaceuticals, Inc.Horizant$81$44,52843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 521 neurology providers in New Jersey.

Other neurology in Secaucus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →